DRREDDYPharmaceuticals
Dr Reddys Laboratories Ltd — Profit & Loss Statement
₹1254.90
-1.46%
Dr Reddys Laboratories Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 117.63 Cr | 134.50 Cr | 29.77 Cr | -116.94 Cr | — |
| Tax Rate For Calcs | 0.25 | 0.23 | 0.25 | 0.27 | — |
| Normalized EBITDA | 9.20K Cr | 8.26K Cr | 7.32K Cr | 4.94K Cr | — |
| Total Unusual Items | 470.50 Cr | 584.80 Cr | 119.10 Cr | -433.10 Cr | — |
| Total Unusual Items Excluding Goodwill | 470.50 Cr | 584.80 Cr | 119.10 Cr | -433.10 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 5.65K Cr | 5.57K Cr | 4.51K Cr | 2.36K Cr | — |
| Reconciled Depreciation | 1.71K Cr | 1.48K Cr | 1.26K Cr | 1.18K Cr | — |
| Reconciled Cost Of Revenue | 13.51K Cr | 11.56K Cr | 10.65K Cr | 10.06K Cr | — |
| EBITDA | 9.67K Cr | 8.84K Cr | 7.44K Cr | 4.51K Cr | — |
| EBIT | 7.96K Cr | 7.36K Cr | 6.18K Cr | 3.33K Cr | — |
| Net Interest Income | -15.20 Cr | 56.70 Cr | -24.80 Cr | 0.70 Cr | — |
| Interest Expense | 282.90 Cr | 171.10 Cr | 142.80 Cr | 95.80 Cr | — |
| Interest Income | 267.70 Cr | 227.80 Cr | 118.00 Cr | 96.50 Cr | — |
| Normalized Income | 5.30K Cr | 5.12K Cr | 4.42K Cr | 2.67K Cr | — |
| Net Income From Continuing And Discontinued Operation | 5.65K Cr | 5.57K Cr | 4.51K Cr | 2.36K Cr | — |
| Total Expenses | 25.35K Cr | 21.39K Cr | 18.68K Cr | 17.85K Cr | — |
| Total Operating Income As Reported | 7.18K Cr | 6.77K Cr | 5.71K Cr | 2.95K Cr | — |
| Diluted Average Shares | 83.42 Cr | 83.35 Cr | 83.19 Cr | 83.17 Cr | — |
| Basic Average Shares | 83.30 Cr | 83.20 Cr | 83.02 Cr | 82.94 Cr | — |
| Diluted EPS | 67.78 | 66.80 | 54.18 | 28.34 | — |
| Basic EPS | 67.88 | 66.93 | 54.29 | 28.42 | — |
| Diluted NI Availto Com Stockholders | 5.65K Cr | 5.57K Cr | 4.51K Cr | 2.36K Cr | — |
| Net Income Common Stockholders | 5.65K Cr | 5.57K Cr | 4.51K Cr | 2.36K Cr | — |
| Net Income | 5.65K Cr | 5.57K Cr | 4.51K Cr | 2.36K Cr | — |
| Minority Interests | -70.10 Cr | 0.00 | 0.00 | — | — |
| Net Income Including Noncontrolling Interests | 5.72K Cr | 5.57K Cr | 4.51K Cr | 2.36K Cr | — |
| Net Income Continuous Operations | 5.72K Cr | 5.57K Cr | 4.51K Cr | 2.36K Cr | — |
| Tax Provision | 1.95K Cr | 1.62K Cr | 1.53K Cr | 873.00 Cr | — |
| Pretax Income | 7.68K Cr | 7.19K Cr | 6.04K Cr | 3.23K Cr | — |
| Other Income Expense | 492.20 Cr | 599.50 Cr | 156.10 Cr | -362.80 Cr | — |
| Special Income Charges | -17.10 Cr | 242.10 Cr | -191.00 Cr | -644.30 Cr | — |
| Gain On Sale Of Ppe | 152.20 Cr | 90.00 Cr | -121.10 Cr | 111.90 Cr | — |
| Impairment Of Capital Assets | 169.30 Cr | 0.30 Cr | 69.90 Cr | 756.20 Cr | — |
| Earnings From Equity Interest | 21.70 Cr | 14.70 Cr | 37.00 Cr | 70.30 Cr | — |
| Gain On Sale Of Security | 487.60 Cr | 342.70 Cr | 310.10 Cr | 211.20 Cr | — |
| Net Non Operating Interest Income Expense | -15.20 Cr | 56.70 Cr | -24.80 Cr | 0.70 Cr | — |
| Interest Expense Non Operating | 282.90 Cr | 171.10 Cr | 142.80 Cr | 95.80 Cr | — |
| Interest Income Non Operating | 267.70 Cr | 227.80 Cr | 118.00 Cr | 96.50 Cr | — |
| Operating Income | 7.20K Cr | 6.53K Cr | 5.91K Cr | 3.59K Cr | — |
| Operating Expense | 11.84K Cr | 9.83K Cr | 8.03K Cr | 7.79K Cr | — |
| Other Operating Expenses | -283.60 Cr | -177.50 Cr | -711.80 Cr | -164.20 Cr | — |
| Research And Development | 2.74K Cr | 2.29K Cr | 1.94K Cr | 1.75K Cr | — |
| Selling General And Administration | 9.39K Cr | 7.72K Cr | 6.80K Cr | 6.21K Cr | — |
| Gross Profit | 19.04K Cr | 16.36K Cr | 13.93K Cr | 11.38K Cr | — |
| Cost Of Revenue | 13.51K Cr | 11.56K Cr | 10.65K Cr | 10.06K Cr | — |
| Total Revenue | 32.55K Cr | 27.92K Cr | 24.59K Cr | 21.44K Cr | — |
| Operating Revenue | 32.55K Cr | 27.92K Cr | 24.59K Cr | 21.44K Cr | — |
| Other Special Charges | — | -152.40 Cr | — | — | — |
| Write Off | — | 0.30 Cr | 69.90 Cr | 756.20 Cr | 858.80 Cr |
| Total Other Finance Cost | — | — | — | — | -165.30 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Dr Reddys Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.